XU Nan , LIANG Derong , MIAO Jia , ZENG Li , ZHANG Huiming
  • Institute of Clinical Pharmacology; West China Hospital; Sichuan University; Chengdu 610041;
Sparfloxacin; lomefloxacin; randomized-controlled trial; acute bacterial infections
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective 　To evaluate the clinical efficacy and safety of domestic sparfloxacin in the treatment of acute bacterial infections.
Methods 　A multicenter randomized controlled clinical trial was conducted. 117 patients were treated with domestic sparfloxacin 200-300 mg qd for 5-14 days and 114 patients were treated with domestic lomefloxacin 300 mg bid for 5-14 days.
Results 　The cure rates and the efficacy rates in each group were 84.62%, 74.56% and 94.87%, 92.98%, respectively. The bacterial clearance rates were 94.28% and 92.02%, respectively. Adverse drug reactions rates were 7.69% and 11.40%, most of them were mild. There were no significant differences of above results between the two groups (P gt;0.05).
Conclusions 　The results suggest that sparfloxacin with wide antibacterial spectrum, satisfactory activity, is an effective and safe antibacterial agent in treatment of mild to moderate acute bacterial infections.

Citation： XU Nan,LIANG Derong,MIAO Jia,ZENG Li,ZHANG Huiming. A multicenter randomized controlled clinical trial on domestic sparfloxacin orally in the treatment of acute bacterial infections. Chinese Journal of Evidence-Based Medicine, 2001, 01(4): 226-232. doi: Copy